Relapsing multiple sclerosis

• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Not authorised
  2023-503631-18-00 5 "Nervous system diseases"
• A Randomized Open Label Trial Exploring the Soluble and Imaging Biomarker Dynamic Responses to Tolebrutinib Compared to Rituximab Treatment … Pending
  2025-523892-50-00 5 "Multiple Sclerosis"
• Ublituximab in Pediatric Participants with Relapsing forms of Multiple Sclerosis (RMS) Recruiting
  2025-522257-19-00 10 2026-05-12 "Relapsing Multiple Sclerosis"
• An open-label study to assess the safety, efficacy, and cellular kinetics of YTB323 (rapcabtagene autoleucel) in Relapsingin Relapsing Multi … Recruiting
  2024-512714-18-00 9 2025-11-11 "Relapsing Multiple Sclerosis"
• A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Site … Recruiting
  2025-523757-33-00 4 2026-05-07 "multiple sclerosis"
• Efficacy and safety of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by o … Recruiting
  2023-509275-17-00 5 2025-10-06
• Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting
  2024-519284-18-00 5 2025-06-18
• A study to investigate long-term safety and tolerability of tolebrutinib in participants with multiple sclerosis Recruiting
  2023-503631-18-01 5 2024-05-20 "Nervous system diseases"
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici … Recruitment ended
  2025-521127-73-00 5 2025-09-12 "Relapsing forms of Multiple Sclerosis"
• Evaluation of intravenous or subcutaneous administration of ublituximab in patients with autoimmune diseases Recruitment ended
  2023-509555-13-00 1 2024-05-15
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Recruitment ended
  2023-509345-12-00 5 2022-06-22 "Multiple Sclerosis"
• A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu … Recruitment ended
  2024-514619-88-00 5 2022-03-18 "Relapsing Multiple Sclerosis"
• A Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adu … Recruitment ended
  2024-514618-11-00 5 2022-03-01 "Relapsing Multiple Sclerosis"
• Efficacy and safety of remibrutinib compared to teriflunomide in participants with relapsing multiple sclerosis, followed by long term treat … Recruitment ended
  2023-509372-41-00 5 2022-01-30 "Multiple Sclerosis"
• A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis Recruitment ended
  2022-502619-13-00 4 2022-01-25 "Relapsing Multiple Sclerosis"
• An Open Label Extension Study of Ublituximab in Subjects with Relapsing Multiple Sclerosis Recruitment ended
  2024-516680-91-00 5 2020-05-21 "relapsing multiple sclerosis"
• A Phase 1 Study of CD19-targeted NEX-T CAR T Cells in Participants with RMS, PMS, or MG(Breakfree-2) Halted
  2023-507820-22-00 3 2024-05-22 "Myasthenia gravis (MG)"
• A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adult … Ended
  2022-502552-31-00 4 2023-10-03 "Relapsing Forms of Multiple Sclerosis"

Showing 1–18 of 18 trials